A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer

INTRODUCTION: Preclinical evidence suggests the feedforward cytokine loop of interleukin-6/Janus kinases (JAK)/STAT3 plays a role in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistance in EGFR-mutated non-small cell lung cancer (NSCLC). METHODS: In this phase 1b study, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Padda, Sukhmani K., Reckamp, Karen L., Koczywas, Marianna, Neal, Joel W., Kawashima, Jun, Kong, Shengchun, Huang, Daniel B., Kowalski, Mark, Wakelee, Heather A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739290/
https://www.ncbi.nlm.nih.gov/pubmed/34773474
http://dx.doi.org/10.1007/s00280-021-04369-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739290/
https://www.ncbi.nlm.nih.gov/pubmed/34773474
http://dx.doi.org/10.1007/s00280-021-04369-0

Ejemplares similares